Research programme: arginase inhibitors - OncoArendi Therapeutics

Drug Profile

Research programme: arginase inhibitors - OncoArendi Therapeutics

Alternative Names: OATD-02

Latest Information Update: 28 Jun 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator OncoArendi Therapeutics
  • Class Antineoplastics; Immunotherapies; Small molecules
  • Mechanism of Action Arginase inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Cancer

Most Recent Events

  • 21 Jun 2017 OncoArendi Therapeutics has patents pending for arginase inhibitors in unknown countries
  • 21 Jun 2017 Early research in Cancer in Poland (PO)
  • 21 Jun 2017 OncoArendi Therapeutics intends to submit an IND application and initiate first in human studies for Cancer in the third quarter of 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top